In Q2 2024, Perceptive Advisors held 91 positions worth $4.0B. They initiated 14 new positions and exited 38. Their largest holding was CERE ($441.4M). Portfolio value shrank -24.3% versus the prior quarter.
Frequently asked questions
What stocks did Perceptive Advisors own in Q2 2024?
Perceptive Advisors held 91 biotech stocks in their 13F portfolio in Q2 2024. Their top positions include CERE, FOLD, ACLX, IOVA, NUVL. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Perceptive Advisors's portfolio worth in Q2 2024?
Perceptive Advisors's tracked biotech portfolio was worth $4.0B across 91 positions, with total assets under management of approximately $8B. Portfolio values are based on 13F filings with the SEC.
What did Perceptive Advisors buy in Q2 2024?
Perceptive Advisors initiated 14 new positions in Q2 2024, including CTNM, RAPP, CGEM, INSM, BCYC and 9 more. They also increased 20 existing positions.
What did Perceptive Advisors sell in Q2 2024?
Perceptive Advisors fully exited 38 positions in Q2 2024, including PRTA, HRMY, BMEA, TVTX, TERN and 33 more. They also trimmed 29 existing positions.
Is Perceptive Advisors a biotech fund?
Clinical-stage biotech specialist known for deep scientific due diligence and concentrated bets on binary catalysts like FDA approvals and pivotal trial readouts. Edelman and team leverage decades of pattern recognition in drug development to identify asymmetric risk/reward setups.
Want AI analysis, insider signals, and catalyst overlays for Perceptive Advisors?
View latest Perceptive Advisors portfolio →